Molecular predictors of response to first-line systemic therapies in advanced hepatocellular carcinoma.

被引：0
|
作者：
Chang, Jeremy
Conner, Elizabeth
Fowler, Kathryn J.
Tamayo, Pablo
Burgoyne, Adam
机构：
[1] Univ Calif San Diego, La Jolla, CA USA
[2] Univ Calif San Diego, San Diego, CA USA
[3] Univ Calif San Diego, Dept Radiol, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-566-9263; 261-566-3248-9542-427-2615; 130-540-543-4790; 3282-270-11593; 283-424-425; 261-566-11347; 3282-206-3691-2722; 8; 6; 4; 3; 1854; 182; 7; 38092-33627; 38092-29187; 38092-20072; 38092-21191; 38092-34303; 2; 1;
D O I：
10.1200/JCO.2024.42.3_suppl.534
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：534 / 534
页数：1
相关论文
共 50 条
  • [1] Quantitative evaluation of the efficacy and safety of first-line systemic therapies for advanced hepatocellular carcinoma
    Xinrui Wang
    Jihan Huang
    Yixiao Liu
    Lijuan Wu
    Ruifen Cai
    Qingshan Zheng
    Lujin Li
    European Journal of Clinical Pharmacology, 2025, 81 (3) : 383 - 393
  • [2] A NETWORK META-ANALYSIS OF FIRST-LINE SYSTEMIC THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA
    Singh, B.
    Sharma, A.
    Rai, P.
    Kaur, G.
    Pandey, S.
    VALUE IN HEALTH, 2023, 26 (06) : S26 - S26
  • [3] Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis
    Celsa, Ciro
    Cabibbo, Giuseppe
    Pinato, David James
    Di Maria, Gabriele
    Enea, Marco
    Vaccaro, Marco
    Battaglia, Salvatore
    Rizzo, Giacomo Emanuele Maria
    Giuffrida, Paolo
    Giacchetto, Carmelo Marco
    Rancatore, Gabriele
    Grassini, Maria Vittoria
    Camma, Calogero
    LIVER CANCER, 2024, 13 (02) : 169 - 180
  • [4] Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis
    Celsa, Ciro
    Cabibbo, Giuseppe
    Di Maria, Gabriele
    Vaccaro, Marco
    Battaglia, Salvatore
    Rizzo, Giacomo Emanuele Maria
    Ciccia, Roberta
    Grova, Alessandro
    Salvato, Mauro
    Giuffrida, Paolo
    Giacchetto, Marco
    Rancatore, Gabriele
    Grassini, Maria Vittoria
    Antonucci, Michela
    Morana, Piera
    Enea, Marco
    Camma, Calogero
    JOURNAL OF HEPATOLOGY, 2023, 78 : S592 - S593
  • [5] Network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: A comparison of objective response rates
    Kaur, G.
    Singh, B.
    Attri, S.
    Sharma, A.
    Rai, P.
    Pandey, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S616 - S616
  • [6] The Impact of Sequential Therapies after First-Line Systemic Therapies in Unresectable Hepatocellular Carcinoma
    Lee, Shou-Wu
    Lee, Teng-Yu
    Yang, Sheng-Shun
    Huang, Yi-Jie
    Peng, Yen-Chun
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (09)
  • [7] NETWORK META-ANALYSIS OF FIRST-LINE SYSTEMIC THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA: WHO IS THE WINNER?
    Celsa, C.
    Cabibbo, G.
    Rizzo, G. E. M.
    Giuffrida, P.
    Di Maria, G.
    Battaglia, S.
    Vaccaro, M.
    Enea, M.
    Giacchetto, C. M.
    Rancatore, G.
    Grassini, M., V
    Ciccia, R.
    Grova, A.
    Salvato, M.
    Camma, C.
    DIGESTIVE AND LIVER DISEASE, 2023, 55 : S106 - S106
  • [8] Network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: Who is the winner?
    Celsa, C.
    Cabibbo, G.
    Rizzo, G. E. M.
    Giuffrida, P.
    Enea, M.
    Di Maria, G.
    Antonucci, M.
    Giacchetto, C. M.
    Rancatore, G.
    Grassini, M. V.
    Ciccia, R.
    Grova, A.
    Salvato, M.
    Battaglia, S.
    Vaccaro, M.
    Camma, C.
    DIGESTIVE AND LIVER DISEASE, 2023, 55 : S3 - S3
  • [9] Considerations for individualized first-line systemic treatment in advanced hepatocellular carcinoma
    Peeters, Frederik
    Dekervel, Jeroen
    CURRENT OPINION IN PHARMACOLOGY, 2023, 70
  • [10] The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma
    Giuliani, Jacopo
    Mantoan, Beatrice
    Bonetti, Andrea
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (02) : 434 - 437
12345